Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Annual Report, Bureau of Health Promotion, Department of Health (DOH), Taiwan 2007.
   Google Scholar
• Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am 2001;28:555–565.
   PubMed Web of Science ®Google Scholar
• Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910–914.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–439.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006;176(4 Part 1):1404–1408.
   Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–1597.
   PubMed Web of Science ®Google Scholar
• Ozcan F. Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure. Eur Urol 2001;40:308–312.
   Google Scholar
• Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5 Part 2):1831–1836.
   Google Scholar
• Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 2001;91:1414–1422.
   PubMed Web of Science ®Google Scholar
• Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004;172:129–132.
   PubMed Web of Science ®Google Scholar
• Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001;166:1322–1327.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. JAMA 1998;280:969–974.
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–771.
   PubMed Web of Science ®Google Scholar
• Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 2002;168:2510–2515.
   Google Scholar
• Ou YC, Chen JT, Yang CR, Cheng CL, Ho HC, Ko JL, Hsieh YS. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer. Jpn J Clin Oncol 2002;32:536–542.
   Google Scholar
• Wu TT, Hsu YS, Wang JS, Lee YH, Huang JK. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 2003;170:78–81.
   PubMed Web of Science ®Google Scholar
• Ho SF, Lao HF, Li K, Tse MK. Clinical results of radical prostatectomy for patients with prostate cancer in Macau. Chin Med J 2008;121:295–298.
   Google Scholar
• Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365–369.
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer Staging. American Joint Committee on Cancer Staging manual, 5th ed. Lippincott Raven Publishers; 1997.
   Google Scholar
• Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58–64.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 2002;60:670–674.
   PubMed Web of Science ®Google Scholar
• Chun FK, Graefen M, Zacharias M, Haese A, Steuber T, Schlomm T, Walz J, Karakiewicz PI, Huland H. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 2006;24:273–280.
   PubMed Web of Science ®Google Scholar
• Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167(2 Part 1):528–534.
   Google Scholar
• National Cancer Registry. Annual Report of Taiwan Cancer Registry; National Cancer Registry; Department of Health, Taiwan. 2006.
   Google Scholar
• Chen CH, Tzai TS, Huang SP, Wu HC, Tai HC, Chang YH, Pu YS. Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups. Urology 2008;72:1287–1292.
   Google Scholar
• Pu YS. Prostate cancer in Taiwan: epidemiology and risk factors. Int J Androl 2000;23(Suppl 2):34–36.
   Google Scholar
• Zhau H, Zhao LS, Chung LWK, Chen BQ, Troncoso P, Kao C, Kojima M, Fraser Symmans W, Zheng N, Palmer JL, Moul JW, Davis R, Ye MF, Xiao LS, Craig Hall M. Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1995;1:51–63.
   Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. PLCO Project Team. N Engl J Med 2009;360:1310–1319.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.
   PubMed Web of Science ®Google Scholar